Ambry Genetics

Ambry Genetics is a leading provider of genetic testing services, established in 1999 by Charles Dunlop. The company is dedicated to advancing the field of clinical genomic diagnostics. As part of REALM IDx, Inc., Ambry Genetics translates complex scientific research into clinically actionable genetic testing solutions. With a history of innovation spanning over two decades, Ambry has established itself as a pioneer in the genetic testing landscape. The company offers a comprehensive suite of tests including hereditary cancer tests, exome sequencing, and more, ensuring that patients and their healthcare providers have access to critical information that can influence health outcomes.

Throughout its journey, Ambry Genetics has achieved multiple milestones, including being the first laboratory to provide groundbreaking tests such as full gene sequencing of CFTR in 2001 and comprehensive hereditary cancer panels in 2012. The company’s laboratory, which operates out of its state-of-the-art facility, is CAP-accredited and CLIA-licensed. Ambry’s continuous commitment to quality and patient care is exemplified through their innovative initiatives, such as the Ambry CARE Program®, which aims to identify patients at increased risk for certain health conditions. By empowering patients and healthcare professionals with actionable insights, Ambry Genetics plays a vital role in the evolving landscape of precision medicine.